Answers are grounded in this paper and cite their sources.
Baicalein is a multi-target flavonoid with broad preclinical anticancer activity, but its clinical translation is limited by poor aqueous solubility, chemical instability, rapid metabolism, and low bioavailability, restricting sustained tumor exposure. Carbon nanodots (CDs) are ultrasmall, surface-tunable, intrinsically fluorescent nanoparticles investigated for drug delivery and theranostic applications. This narrative review integrates baicalein’s anticancer mechanisms, delivery barriers, and CD-based formulation strategies to establish mechanistically grounded design principles for baicalein–CDs systems. A structured search of PubMed and Google Scholar (1988–January 2026) was conducted using baicalein-, carbon nanodot-, and cancer-related keywords, followed by thematic synthesis and qualitative appraisal of nanomaterial characterization and experimental rigor. Baicalein–CDs systems can be developed through physical loading, covalent conjugation, or hybrid approaches. Their performance is influenced by nano–bio interface interactions, including π–π stacking, hydrogen bonding, electrostatic interactions, and protein corona formation, which affect stability, drug retention, release behavior, and cellular uptake. Existing studies demonstrate successful baicalein loading or conjugation and report promising in vitro anticancer-related effects. However, most evidence remains preliminary, with limited serum-stability evaluation, inconsistent benchmarking, inadequate quantification of drug association, and insufficient in vivo biodistribution and safety data. This review proposes a minimum translational framework emphasizing standardized physicochemical characterization, stability and release studies in biologically relevant media, and pharmacokinetic, biodistribution, and toxicity evaluations aligned with chemistry, manufacturing and controls (CMC) principles. Overall, baicalein–CDs represent a promising but early-stage nanomedicine platform requiring stronger mechanistic and translational validation.
No takes yet. Share an insight, caveat, or question.
Zahid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: